Specifically, non-competitive allosteric inhibitors of CXCR2, limit systemic inflammation in streptozotocin-treated mice, reverse diabetes in NOD mice [46], improve hepatic insulin resistance, liver damage and inflammation in experimental models of HFD feeding [47] and in models of non-alcoholic fatty liver disease [48]. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.